A5011221036- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Neuroblastoma Research and Treatments
- Monoclonal and Polyclonal Antibodies Research
- HER2/EGFR in Cancer Research
- Photodynamic Therapy Research Studies
- Pituitary Gland Disorders and Treatments
- Cancer Cells and Metastasis
- CAR-T cell therapy research
- Radiopharmaceutical Chemistry and Applications
The University of Texas Health Science Center at Houston
2018-2021
Brown Foundation
2018-2021
Baylor College of Medicine
2020
Clinically available intraoperative imaging tools to assist surgeons in identifying occult lesions are limited and partially responsible for the high rate of disease recurrence patients with neuroendocrine tumors (NET). Using established clinical efficacy radiolabeled somatostatin analogs as a model, we demonstrate ability fluorescent analog selectively target that overexpress receptor subtype-2 (SSTR2) utility fluorescence-guided surgery (FGS).A multimodality chelator (MMC) was used...
Leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5) is highly expressed in colorectal tumors and marks colon cancer stem cells that drive tumor growth metastasis. Recently, we showed LGR5 a promising target for antibody–drug conjugate (ADC) therapy. However, it important to identify LGR5-positive would respond ADC treatment. Prior drug conjugation, evaluated two different anti-LGR5 monoclonal antibodies (mAbs), 8F2 9G5, using 89Zr-immunoPET select the optimal mAb development...
Background. Although therapeutic advances have led to enhanced survival in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer, detection of residual disease remains challenging. Here, we examine two approved anti-HER2 monoclonal antibodies (mAbs), trastuzumab and pertuzumab, as potential candidates for the development immunoconjugates fluorescence-guided surgery (FGS). Methods. mAbs were conjugated near-infrared fluorescent (NIRF) dye, IRDye800, quantitative...
<p>Supplementary figures and tables. "Clean" version.</p>
<p>Supplementary figures and tables. "Clean" version.</p>
<div>AbstractPurpose:<p>Clinically available intraoperative imaging tools to assist surgeons in identifying occult lesions are limited and partially responsible for the high rate of disease recurrence patients with neuroendocrine tumors (NET). Using established clinical efficacy radiolabeled somatostatin analogs as a model, we demonstrate ability fluorescent analog selectively target that overexpress receptor subtype-2 (SSTR2) utility fluorescence-guided surgery...
<div>AbstractPurpose:<p>Clinically available intraoperative imaging tools to assist surgeons in identifying occult lesions are limited and partially responsible for the high rate of disease recurrence patients with neuroendocrine tumors (NET). Using established clinical efficacy radiolabeled somatostatin analogs as a model, we demonstrate ability fluorescent analog selectively target that overexpress receptor subtype-2 (SSTR2) utility fluorescence-guided surgery...
Abstract Background: Although advances in neoadjuvant and adjuvant treatments have led to enhanced survival patients with HER2 positive breast cancer, intraoperative detection of residual disease tumor margins (including DCIS) remain challenging. Real-time fluorescence imaging is being used during surgery improve visualization identify margins. However, the lack an approved agent that specific for expressing cancers limits utility fluorescence-guided (FGS) this patient population. We...